Transaction DateRecipientSharesTypePriceValue
21st October 2020Michael Aaron Kelly5,754Grant/award etc.$0.00
30th September 2020Bruce K Crowther1,036Grant/award etc.$43.62$45,190.32
29th September 2020Steven C Jones81,000Open or private sale$36.55$2,960,550.00
29th September 2020Steven C Jones141,049Open or private sale$36.95$5,211,760.55
29th September 2020Steven C Jones25,000Bona fide gift$0.00
28th September 2020Steven C Jones38,951Open or private sale$36.34$1,415,479.34
28th September 2020Steven C Jones19,000Open or private sale$36.56$694,640.00
24th September 2020Bruce K Crowther8,333Exercise of derivative$9.11$75,913.63
24th September 2020Bruce K Crowther8,333Open or private sale$35.01$291,738.33
22nd September 2020Bruce K Crowther2,400Open or private sale$35.68$85,632.00
Neo Genomics
Neo Genomics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

NeoGenomics, Inc. specializes in cancer genetics diagnostic testing and pharma services. It operates through two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research.

Ticker: NEO
Sector: Health Services
Industry: Medical/Nursing Services
SEC Central Index Key (CIK): 1077183
Employees: 1700
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $295 M (0%)
Inventory, Net: $22 M (50%)
Other Assets, Current: $6 M (119%)
Assets, Current: $419 M (44%)
Property, Plant and Equipment, Net: $84 M (30%)
Other Assets, Noncurrent: $3 M (7%)
Assets: $945 M (33%)
Long-term Debt, Current Maturities: $0 (-100%)
Accounts Payable, Current: $19 M (-1%)
Liabilities, Current: $62 M (-3%)
Other Liabilities, Noncurrent: $3 M (-11%)
Liabilities: $291 M (44%)
Common Stock, Shares, Issued: $110 M (5%)
Additional Paid in Capital, Common Stock: $679 M (30%)
Retained Earnings (Accumulated Deficit): $25 M (121%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $43 Th (-97%)
Stockholders' Equity (Parent): $654 M (0%)
Liabilities and Equity: $945 M (33%)
Cost of Revenue: $59 M (-50%)
Gross Margin: $28 M (0%)
Research and Development: $2 M (0%)
Sales and Marketing: $10 M (0%)
General and Administrative Expenses: $35 M (0%)
Operating Income/Loss: $19 M (0%)
Provision for income taxes: $11 M (0%)